METHODS
Subjects with mild renal impairment (n = 12), moderate impairment (n = 12), or their matched healthy controls (n = 25) participated in this study. Subjects received a single dose of pridopidine (45 mg) on day 1 and a multiple dose cycle of 45 mg once daily on days 5-18. Blood and urine samples were collected on days 1 and 18 for PK analysis.
RESULTS
Mild renal impairment did not affect the PK of pridopidine whilst an increase in exposure was seen in subjects with moderate renal impairment. Subjects with moderate impairment showed reduced plasma clearance (by 44%) and had 68% higher AUC (90% CI 1.22, 2.30) and 26% higher C max (90% CI 1.02, 1.56) values than those with normal renal function at steady-state. Pridopidine was safe and well tolerated in healthy subjects and in subjects with mild and moderate renal impairment.
CONCLUSIONS
Mild renal impairment has no impact on exposure to pridopidine while moderately impaired renal function resulted in higher pridopidine concentrations.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Pridopidine is a drug under clinical development for the treatment of motor symptoms in Huntington's disease.
• Renal elimination is the most important elimination pathway for pridopidine at steady-state. However the impact of renal impairment on its clinical pharmacokinetics have not been characterized.
• This phase 1 study was performed to characterize the pharmacokinetics pridopidine in subjects with normal and mild or moderately impaired renal function, to enable appropriate dosing recommendations for these special patient populations.
Introduction
Huntington's disease (HD) is a rare neurodegenerative disorder of the central nervous system (CNS) with an autosomal dominant model of inheritance and a prevalence of 1/100 000 to 5/100 000 [1, 2] . HD is caused by mutant huntingtin gene (mHTT) protein aggregation which leads to progressive destruction of a wide variety of proteins, causing metabolic dysfunction and eventual cell death mainly in the striatum. The neurodegeneration in the striatal pathways leads to the characteristic symptoms such as involuntary choreatic movements and behavioural and psychiatric abnormalities, which aggravate with progression of the disease. Patients are on average between 30 and 50 years old at onset of the first symptoms [1, 2] . Pridopidine (4-[3-(methylsulfonyl)phenyl]-1-propylpidperidine, formerly known as ACR16), is a drug under clinical development for the treatment of motor symptoms in HD. It belongs to a new class of pharmaceutical agents, the dopidines which are considered to have dopamine stabilizing properties. Pridopidine presumably restores balance in the cortico-striatal pathway that controls motor function disrupted in HD [3] . In clinical trials conducted in HD patients, pridopidine at a dose of 45 mg twice daily non-significantly improved the modified motor score (mMS) and significantly improved the total motor score (TMS) of the Unified Huntington's Disease Rating Scale (UHDRS). In both studies, pridopidine was considered safe and well tolerated with a benign adverse event (AE) profile [4] [5] [6] .
Pridopidine is absorbed relatively rapidly after oral administration with a t max between 0.5 to 4 h [7] , and a dose proportional increase in exposure for dose levels from 10 mg twice daily to 90 mg twice daily at steadystate [8] . Pridopidine's elimination half-life after multiple doses is about 10-14 h [7] and it is approximately 30% bound to plasma proteins (data on file). Pridopidine is metabolized by the polymorphic enzyme CYP2D6 by N-depropylation to TV-45065 (previously named ACR30, a major metabolite assumed to be pharmacologically inactive based on in vitro and preclinical testing). The contribution of the CYP2D6 pathway to pridopidine's elimination after a single dose depends on the patient's 2D6 genotype (whether they are an extensive or poor CYP2D6 metabolizer) but over time pridopidine inhibits its own CYP2D6-driven metabolism [9] . Thus at steady-state, for all patients and regardless of the CYP2D6 genotype, renal excretion becomes the most important route of elimination of pridopidine and TV-45065 [7] .
This trial was conducted to assess the influence of renal function on the pharmacokinetics of pridopidine, by evaluating its pharmacokinetics in subjects with impaired vs. normal renal function, in order to provide appropriate dosing recommendation in the patient setting.
Methods
The study (EudraCT-number 2009-013 158-34) was conducted at two sites in Germany in accordance with the Declaration of Helsinki [10] and the ethical principles of Good Clinical Practice [11] . The competent authority, the leading ethics committee of the Medical Association of Baden-Württemberg, Germany and the local ethics committee of the Medical Association of Schleswig-Holstein, Germany approved the trial. All participants provided written informed consent before the start of the trial.
The study population consisted of male and female subjects, aged between 18 and 75 years, weighing at least 50 kg, and having a body mass index between 18 and 34 kg m -2 . Renal function was assessed at screening based on creatinine clearance (CL cr ) as an estimation of the glomerular filtration rate (eGFR), and calculated using the Modified Diet in Renal Disease (MDRD) equation [12] . Renal function was classified as normal when CL cr was ≥90 ml min -1 , as mildly impaired when CL cr was ≥60 to 89 ml min -1 and moderately impaired when CL cr ≥30 to 59 ml min -1 . For each subject with renal impairment, a healthy subject of the same gender was included, matched by age (±5 years) and body weight (±10 kg). There were two groups of subjects with renal impairment (mild and moderately impaired) and two matching groups of healthy volunteers with normal renal function.
Study subjects were screened to exclude CYP2D6 poor metabolizers. The following alleles were analyzed: *2, *3, *4, *5, *6, *7, *8, *9, *10, *35, *41, *MxN and genotype was assigned according to four categories ((ultrarapid metabolizers (UM), extensive metabolizers (EM), intermediate metabolizer (IM) and poor metabolizers (PM)). EMs have at least one functional CYP2D6 allele, IMs have two CYP2D6 alleles with reduced function or one reduced and one non-functional allele and PMs have two non-functional alleles. Other key exclusion criteria included severe impairment of renal function or requiring dialysis, smoking more than five cigarettes day À1 or unable to abstain from smoking during confinement period, pregnant or nursing females, prolonged QT c interval at screening (defined as a QT c interval of >450 ms for males or >470 ms for females) or history of QT c prolongation or other ECG abnormalities including syncopes of unclear genesis in medical history, personal or familial history of seizures or significant cardiovascular events within 6 months. Subjects with renal impairment who required treatment for renal impairment or other chronic disease on a stable treatment plan for at least 2 months prior to dosing could be enrolled unless the treatment was excluded (inducers or inhibitors of CYP2D6, tricyclic antidepressants, or class I anti-arrhythmic drugs).
Trial design
The trial design followed the recommendations of the FDA [13, 14] and EMA [15] guidances related to the investigation of pharmacokinetics in patients with impaired renal function. This study was open label and no randomization was required. As pridopidine exhibits non-linear and time-dependent pharmacokinetics, the study included assessments not only after single but also after multiple dose administration. Pridopidine exposure in subjects with mild renal impairment was evaluated before proceeding with the dosing of the moderate impairment group. No formal sample size estimation was performed. However a sample size of 12 subjects per group was considered to be adequate to meet the study goals and is commonly used in this kind of study.
Treatments were administered orally as 45 mg pridopidine capsules. The treatment period consisted of a single dose cycle (pridopidine administration on day 1) and a multiple dose cycle with 14 days of once daily administration (days 5 to 18). On days 1 and 18 (pharmacokinetic profile days), subjects were fasted for at least 10 h prior to dosing.
Blood and urine sampling
Blood samples for quantification of pridopidine and TV-45065 were collected before and 0. Concentrations of pridopidine and its metabolite, TV-45065, were determined in potassium EDTA plasma and urine by validated methods using liquid chromatography and tandem mass spectrometric detection (LC-MS/MS). For both plasma and urine, the samples were made basic by the addition of sodium hydroxide and the analytes were isolated using liquid-liquid extraction into diethyl ether. The analytes were resolved isocratically with a mobile phasecomposedofwater :acetonitrile:methanol: concentrated ammonia, 1000 : 250 : 500 : 3, v/v with 0.5 g of ammonium acetate at a flow rate of 0.6 ml min on a Waters X-Bridge Phenyl column (100 × 3 mm; 3.5 μm particle size). Quantification was performed using peak area ratios with respect to internal standards (d7-pridopidine for the parent and a structural analogue, ACR481, for the metabolite). The analytes were monitored using electrospray ionization in the positive ion mode on a Sciex API 500. The mass transitions monitored were m/z 282. For plasma, weighted (1/concentration 2 ) linear regression analysis was used to determine concentrations over a range of 1.849 to 397.194 ng ml -1 , and 1.872 to 376.514 ng ml -1 for pridopidine and TV-45065, respectively. During validation, the bias for pridopidine in plasma ranged from À3.30 to À0.39%, with a coefficient of variation (CV) of ≤6.65%. The bias of TV-45065 ranged from À8.64 to 3.21%, with a CV of ≤13.61%. The urine method utilized weighted (1/concentration 2 ) linear regression analysis to determine concentrations over a range of 0.062 to 25.465 μg ml -1 for pridopidine and 0.060 to 24.672 μg ml -1 for TV-45065. During validation, the bias for pridopidine in urine ranged from 0.99 to 2.31%, with a CV of ≤3.51%. The bias of TV-45065 ranged from 1.41 to 4.29%, with a CV of ≤6.32%. Methods were demonstrated to be selective for pridopidine and TV-45065.
Calculation of pharmacokinetic parameters
Pharmacokinetic and statistical analyses were performed for pridopidine and TV-45065 plasma and urine data from subjects with sufficient data for reliable analysis.
Pharmacokinetic parameters were calculated for both single and multiple doses from the individual concentrations by non-compartmental procedures using SAS® version 9.2 (SAS Institute, Cry, NC, USA). Plasma concentrations below LLOQ observed between administration and first quantifiable concentration were set to zero for calculation of pharmacokinetic parameters. All other concentrations below LLOQ were excluded from calculations. Concentrations in urine below the LLOQ were set to zero for calculation of the amount excreted.
The plasma PK parameters calculated were the observed maximum plasma concentration (C max ), the time from dosing to C max (t max ), the area under the plasma concentration vs. time curve (AUC) extrapolated to infinity (for single dose, AUC(0,∞)) and over one dosing interval (AUC(0,τ ss ) for multiple dose), which were calculated using the log-linear trapezoidal formula. The apparent terminal half-life (t 1/2 ) was calculated after single dose and at steady-state from the slope of the terminal phase, apparent clearance (CL/F) was calculated as the quotient of AUC(0,∞) after single dose or AUC(0,τ ss ) at steady-state and dose and apparent volume of distribution (V z /F) was calculated as the quotient of CL/F and terminal slope. The accumulation index (Rac) was calculated as the quotient of AUC(0,τ) at steady-state and AUC(0,24 h) after a single dose.
The calculated urine PK parameters included renal clearance (CL R ) calculated as the ratio of the amount excreted over AUC (up to 72 h for single dose, and over a dosing interval for steady-state assessments, respectively), and the fraction of dose excreted in urine (f e ), calculated as amount excreted/dose in a similar way. Adjustment by the molecular weights (TV-45065/pridopidine, i.e. 239.34/281.42) was applied when relevant.
Statistical analyses
An analysis of variance (ANOVA) on trough plasma concentrations on days 15 to 18 was performed to confirm steady-state. The effect of renal impairment on pridopidine pharmacokinetics was examined using ANOVA of AUC(0,∞), C max (single dose) and AUC(0,τ ss ), and C max,ss (steady-state) (MIXED procedure, SAS) following logarithmic transformation. Each of the renally impaired groups was compared with the matching normal renal function group with a statistical significance level of alpha =0.05. Point estimates and corresponding 90% confidence interval (CI) for geometric means of 'impaired/healthy' ratios of pharmacokinetic parameters were separately calculated for comparison of each renal impairment group with the corresponding healthy matching subject group.
The relationships between CL cr and pharmacokinetic parameters C max and AUC were also investigated graphically by plotting the individual values of creatinine clearance against the log (ln) transformed pharmacokinetic variable.
Safety evaluation
Safety measurements of all subjects receiving at least one dose of study medication were based on incidence and severity of treatment-emergent adverse events (TEAEs), vital signs, ECG, physical examination and safety laboratory tests at the follow-up safety visit. Adverse events observed from first administration of pridopidine to the safety follow-up visit (5 to 7 days after last administration) were considered for safety assessment. During outpatient periods, subjects were to report any adverse events to the investigator by phone.
Results
Forty-nine subjects were enrolled and 48 completed the study and were part of the PK analysis (12 subjects on each group). One healthy subject matched to one mildly impaired subject was withdrawn due to an adverse event (renal colic due to urethral calculus) after the first dose of pridopidine and a replacement was recruited. All study subjects were extensive metabolizers except for four subjects who were intermediate metabolizers (one with normal renal function, two with mild renal impairment and one with moderate renal impairment). Demographic characteristics of the study population are presented in Table 1 . On average, subjects with moderate renal impairment (and hence their matched controls) were older than those with mild renal impairment (and controls), with mean age of 61. 5 
Pharmacokinetic results
After a single dose of 45 mg pridopidine, mean plasma concentration-time profiles of pridopidine and its metabolite TV-45065 were comparable between subjects with mild renal impairment and their matched healthy subjects. In subjects with moderate renal impairment, the mean plasma concentration profiles of pridopidine were higher than in matched healthy subjects ( Figure 1A ). Steady-state was confirmed after 14 days of dosing as point estimates of ratios day 15 : day 16, day 16 : day 17 and day 17 : day 18 were near 1.00 and all 90% confidence limits were within the equivalence range of 0.80-1.25. Plasma concentrations of pridopidine were higher at steady-state compared with single dose in all groups, indicating accumulation ( Figure 1B) . The plasma concentration of pridopidine in subjects with moderate renal impairment was higher than in matched controls, the same trend as seen after a single dose. Plasma concentrations of TV-45065 showed the same trend as the parent, and were slightly lower at steady-state compared with single dose (Figure 2 panels A and B) .
Single dose administration of pridopidine resulted in comparable PK parameters for the mild renally impaired subjects and their matched healthy controls (Table 2 ). In subjects with moderate renal impairment, exposure to pridopidine was higher than in the healthy control group, with about 50% higher AUC(0,∞) (3087 vs. 2059 ng ml -1 h) but similar C max (Table 3) . Total CL/F of the subjects with moderate renal impairment was 25% Table 1 Key demographic characteristics of study subjects included in the PK analysis Pharmacokinetics of pridopidine in subjects with renal impairment lower than that observed in the control group (312 ml min -1 vs. 410 ml min -1 ), while CL R was almost the same (72.8 ml min -1 and 75 ml min -1 , respectively). The lower CL/F resulted in a prolongation of the half-life in subjects with moderate renal impairment compared with the healthy control group. The metabolite displayed similar findings to the parent compound.
Multiple dose administration of pridopidine resulted in increased exposure to pridopidine in all study subjects compared with single dose due to drug accumulation (Tables 2 and 3 ). The extent of the changes seen was similar between the mild renal impairment group and its matched control group. Total clearance (CL/F ss ) decreased by about 45% after multiple dosing compared with single dose) with a corresponding increase of 65% in AUC (from 2365 ng ml -1 h to about 3900 ng ml -1 h in both groups). C max increased with multiple dosing by about 30% in mild renal impairment and 60% in the matched control group. Renal clearance did not differ markedly between single and multiple dose administration.
The decrease in total clearance in subjects with moderate renal impairment with multiple dosing compared with single dose was only slightly higher than any other groups (À56%, from 312 to 137 ml min -1 Table 3 ). As a result of the change in clearance, and with drug accumulation over time, the difference in exposure between the moderate renally impaired group and its control was accentuated at steady-state and AUC(0,τ ss ) and C max,ss were approximately 80% and 30% higher in the impaired group as compared with the matched healthy group, respectively. One subject in the moderately impaired group had an AUC(0,τ ss ) and C max,ss which were twice as high as the next highest subject. As the subject was the eldest amongst the moderate renally impaired subjects (subject was a 74-year-old female), this increased exposure could be also related to age (but not entirely).
Renal clearance after single and multiple dosing were approximately similar in subjects with moderate impairment and the matched control subjects. ANOVA did not show significant differences between healthy subjects and subjects with mild renal impairment regarding pridopidine AUC and C max , with point estimates ranging from 0.86 to 1.06 at both dosing administrations (Table 4) . In subjects with moderate renal impairment, both mean AUC and C max were higher compared with the means of the matched healthy group after multiple dosing, Semilogarithmic plots of the plasma concentrations of the metabolite TV45065 after single and multiple dose administrations of pridopidine to healthy and renally-impaired subjects. normal matched to mild renal impairment, normal matched to moderate renal impairment, mild renal impairment, moderate renal impairment with point estimates of 1.26 and 1.68 for C max,ss and AUC(0,τ ss ), respectively (statistically significant only for AUC(0,τ ss ). Regression analysis of the ln-transformed PK parameters also indicated a significant effect of CL cr on AUC(0,τ ss ) (slope = À0.008, P < 0.001) but not on C max,ss ( Figure 3) . In all groups after multiple dosing, the fraction of the parent compound excreted in urine as unchanged Table 3 Pharmacokinetic parameters of pridopidine and its metabolite TV-45065 after single and multiple daily doses of 45 mg pridopidine to subjects with moderate renal impairment and normal renal function Pharmacokinetics of pridopidine in subjects with renal impairment pridopidine rose compared with a single dose, ranging from about 30% to 50% of the administered dose, and matched by a respective decrease in the fraction of excreted metabolite (Tables 2 and 3 ). The total fraction excreted (pridopidine and metabolite) remained relatively constant, between 70% and 80% of the administered dose.
Safety
During the study, 56 AEs were observed in 25 of the 49 subjects (51%). The most common adverse events in this study were headache (14 events in nine subjects), dizziness (six events in five subjects), nasopharyngitis (six events in six subjects) and fatigue (five events in five subjects). Events occurring more than once are presented in Table 5 ; sixty percent (60%), 67% and 17% of subjects with normal, mild, and moderately impaired renal function reported adverse events, respectively. All adverse events were resolved at the end of the study.
No deaths and no serious adverse events were observed. One subject (normal renal function, male, 49 years) was withdrawn from the trial 2 days after the first dose due to an adverse event (renal colic due to urethral calculus) not related to the study medication. Safety laboratory parameters, vital signs and ECG parameters showed no influence of pridopidine administration. None of the subjects with normal renal function showed clinically relevant changes in safety laboratory parameters. In the subjects with renal impairment, clinically relevant abnormal values in safety laboratory values were due to the underlying renal impairment. Overall, once daily treatment with 45 mg pridopidine over 14 days was safe and well tolerated in healthy subjects and in subjects with mild and moderate renal impairment.
Discussion
After oral absorption, pridopidine is eliminated partly by urinary excretion and partly by hepatic metabolism, primarily via the CYP2D6 pathway. Pridopidine is metabolized in extensive metabolizers by CYP2D6 to TV-45065, while the contribution from other enzymatic pathways does not seem to be significant (data on file). Individuals who are poor CYP2D6 metabolizers depend on renal excretion as their main elimination pathway. It has been shown that during multiple dose administration, pridopidine can inhibit its own CYP2D6-driven metabolism, meaning that upon repeated dosing, renal elimination becomes a more important elimination pathway than the CYP2D6-driven metabolism [7] . The present study assessed the influence of renal function on the pharmacokinetics of pridopidine and TV-45065. Log (ln)-transformed regression analysis of AUC (A) and C max (B) at steady-state. * This subject was the oldest subject in the trial (74-yearold female) and was only partially age-matched to a 67-year-old subject
The pharmacokinetic parameters measured in the healthy controls in this group were consistent with those previously reported in extensive metabolizers, both after single and multiple dose [7, 16] . Consistent with these studies, the apparent total clearance was about 50% lower at steady-state than after single dose in all study subjects, while renal clearance was stable over time. In addition, exposure to the CYP2D6-formed metabolite TV-45065 was reduced in all groups following multiple doses. The decrease in total clearance can therefore be linked to the decrease in non-renal clearance (i.e. inhibition rather than saturation of CYP2D6 metabolism) both in normal and renally impaired subjects. In agreement with this mechanism, the fraction of unchanged pridopidine excreted in urine increased over multiple dosing, together with a matching decrease of metabolite excretion, so that a total of about 70-80% of the dose was excreted in urine either as the parent or TV-45065 after both single and multiple doses. Renal clearance of pridopidine for all subjects was close to the glomerular filtration rate (GFR), suggesting as previously reported that renal excretion of pridopidine occurs by passive filtration [7, 16] .
In subjects with mild renal impairment (creatinine clearance ≥60 to 89 ml min -1 ), the pharmacokinetics of pridopidine was similar to that observed in the matched healthy subjects (creatinine clearance ≥90 ml min -1 ), indicating that mild renal impairment has no significant impact on pridopidine exposure, after either single or multiple dosing.
Subjects with moderate renal impairment (creatinine clearance ≥39 to 59 ml min -1 ) on the other hand exhibited lower total clearance than their matched healthy controls, which resulted in higher pridopidine exposure. A 74-year-old female subject with a CL cr of 34 ml min -1 exhibited a pridopidine AUC and C max that was almost double that of the next highest individual. However it is unknown whether her extreme exposure was due to the low CL cr or age. If the latter, then the true impact of moderate renal impairment could be lower than expected. Interestingly, the increase in plasma exposure was not fully reflected by differences in renal clearance in the respective groups (Table 3) . A potential reason for this could be the difficulty related to the urine measurements as opposed to plasma (imprecision in measuring renal clearance, possible inhibition of other elimination paths by renal impairment-related toxins, small number of subjects).
As expected, C max was less affected by renal impairment than AUC, as reflected both by the ANOVA analysis and correlation analyses with eGFR. Moderate impairment can further be distinguished between Stage 3a (GFR 45-59 ml min ). Although the impact of renal impairment was not analyzed for each moderate subgroup, Figure 3 shows that both subgroups were represented in the study (with five subjects falling into the 3a and seven subjects falling into the 3b category), and provides a relationship between the renal clearance rates and the C max and AUC parameters for the full evaluated GFR range.
Renal elimination of unchanged pridopidine is the main route of elimination in both CYP2D6 EMs and PMs at steady-state. In PMs, renal clearance accounts for nearly the total clearance, while in EMs it accounts for about 70% of the total clearance, with the remaining CL/F mediated by the residual CYP2D6 activity not inhibited at steady-state [7] . This study excluded CYP2D6 PMs in order to reduce variability and eliminate confounding factors. Most subjects were EMs, and from review of the data the four enrolled IM subjects did not affect the conclusions. Also, the evaluation described in this work was conducted at 45 mg once daily, whilst clinical trials with pridopidine are being conducted with doses up to 112.5 mg twice daily Table 5 Adverse events occurring more than once during the study Normal renal function (n = 25)
Mild renal impairment (n = 12) Moderate renal impairment (n = 12) Total (n = 49)
Adverse events F, n, % F, n, % F, n, % F, n, % F, Number of events; n, number of subjects; %, the percent of treated subjects
Pharmacokinetics of pridopidine in subjects with renal impairment [17] . As the inhibition of CYP2D6 in EMs results in enzyme inactivation and a steady-state pharmacokinetic profile comparable with those of the CYP2D6 PMs [7] , the results of steady-state pharmacokinetics obtained for CYP2D6 EMs in this study could also be cautiously extrapolated to the poor metabolizer population. The most conservative scenario for consideration when extrapolating these steady-state results to higher daily doses of pridopidine and/or poor metabolizers would be a complete knock-out of non-CL R , whether due to non-functional CYP2D6, greater auto-inhibition at higher doses and/or accumulation at steady-state. In such a case, CL/F could approximate CL R and dosing could be sought to be adjusted accordingly. Population pharmacokinetic analyses including data generated at higher doses and in individuals with different degrees of CYP2D6 activity will enable the prediction of exposure for specific populations. These analyses could also address the potential impact of age on pridopidine pharmacokinetics. Finally, despite the increased exposure in subjects with moderately impaired renal function, no obvious relationship between renal function and number and nature of adverse events or other safety parameters was observed. In this study, pridopidine was well tolerated in healthy subjects as well as in those with renal impairment.
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